Tango Therapeutics, Inc. - 8-K Filing
Tango Therapeutics held its annual stockholder meeting on June 4, 2026, where three Class II directors (Malte Peters and Mace Rothenberg were elected), the ratification of PricewaterhouseCoopers as auditors was approved with 99.9% support, and executive compensation received approval from 87.5% of votes cast. (Items: 5.07 Submission of Matters to a Vote of Security Holders)
Tickers: $TNGX